Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trinity Biotech ( (TRIB) ) just unveiled an update.
Trinity Biotech has released its Annual Report for 2024, which includes key documents such as the Company Secretary’s letter, Notice of Annual General Meeting, and AGM Proxy Card. The report, dated September 8, 2025, provides insights into the company’s financial performance, strategic direction, and management structure, highlighting the leadership of CEO John Gillard. This announcement is significant for stakeholders as it outlines the company’s operational and financial status, potentially impacting its market position and investor confidence.
The most recent analyst rating on (TRIB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. While technical analysis shows some positive momentum, the poor valuation metrics further weigh down the score.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech is a company based in Bray, County Wicklow, Ireland, specializing in the development and commercialization of diagnostic products. The company operates in the biotechnology industry and focuses on providing diagnostic solutions for various medical conditions.
Average Trading Volume: 5,236,176
Technical Sentiment Signal: Hold
Current Market Cap: $20.94M
Learn more about TRIB stock on TipRanks’ Stock Analysis page.